Literature DB >> 16932567

Origins of brain tumors--a disease of stem cells?

Elena I Fomchenko1, Eric C Holland.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16932567     DOI： 10.1038/ncpneuro0200

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN： 1745-834X


× No keyword cloud information.
  3 in total

1.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  J Neurooncol       Date:  2009-07-11       Impact factor: 4.130

Review 3.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.